Voor wie we er zijnOnze wetenschapProductenResultaten
InloggenVraagAan de slagvanaf $ 449
Kenmerk
Chest pain
An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) localized to the chest.
Samenvatting
- Ook bekend als
- Thoracic pain
- Lichaamssysteem
- Constitutional symptom
Chest painHP:0100749
Voor wie we er zijnOnze wetenschapProductenResultaten
InloggenVraagAan de slagvanaf $ 449
Read the genes linked to Chest pain, and the rest of your genome, with one test.
Vanaf $ 449Gratis verzending · Resultaten binnen 6–8 weken
Mijn Genome Test bestellen143 genen gekoppeld aan Chest pain
Veranderingen in deze genen veroorzaken zeldzame aandoeningen waarbij Chest pain voorkomt. De meeste mensen met dit kenmerk hebben geen van die aandoeningen, en een gen op deze lijst zegt niets over het eigen genoom van iemand.
| Gen | Hoe vaak het voorkomt | Aandoeningen |
|---|---|---|
| EMDemerin | Altijd | In 1 aandoening |
| POPDC2popeye domain cAMP effector 2 | Altijd | In 1 aandoening |
| SOX17SRY-box transcription factor 17 | Altijd | In 1 aandoening |
| CALRcalreticulin | Heel vaak (80–99%) | In 1 aandoening |
| JAK2Janus kinase 2 | Heel vaak (80–99%) | In 2 aandoeningen |
| MPLMPL proto-oncogene, thrombopoietin receptor | Heel vaak (80–99%) | In 2 aandoeningen |
| SH2B3SH2B adaptor protein 3 | Heel vaak (80–99%) | In 1 aandoening |
| TET2tet methylcytosine dioxygenase 2 | Heel vaak (80–99%) | In 1 aandoening |
| TP53tumor protein p53 | Heel vaak (80–99%) | In 1 aandoening |
| TSC1TSC complex subunit 1 | Heel vaak (80–99%) | In 1 aandoening |
| TSC2TSC complex subunit 2 | Heel vaak (80–99%) | In 1 aandoening |
| ABCC9ATP binding cassette subfamily C member 9 | Vaak (30–79%) | In 1 aandoening |
| ACTA2actin alpha 2, smooth muscle | Vaak (30–79%) | In 1 aandoening |
| BAP1BRCA1 associated deubiquitinase 1 | Vaak (30–79%) | In 1 aandoening |
| BTNL2butyrophilin like 2 | Vaak (30–79%) | In 2 aandoeningen |
| CDH2cadherin 2 | Vaak (30–79%) | In 1 aandoening |
| CFTRCF transmembrane conductance regulator | Vaak (30–79%) | In 1 aandoening |
| COL3A1collagen type III alpha 1 chain | Vaak (30–79%) | In 1 aandoening |
| COL4A5collagen type IV alpha 5 chain | Vaak (30–79%) | In 1 aandoening |
| COL4A6collagen type IV alpha 6 chain | Vaak (30–79%) | In 1 aandoening |
| CRLF1cytokine receptor like factor 1 | Vaak (30–79%) | In 1 aandoening |
| CTLA4cytotoxic T-lymphocyte associated protein 4 | Vaak (30–79%) | In 1 aandoening |
| DLEC1DLEC1 cilia and flagella associated protein | Vaak (30–79%) | In 1 aandoening |
| DLSTdihydrolipoamide S-succinyltransferase | Vaak (30–79%) | In 1 aandoening |
| DNMT3ADNA methyltransferase 3 alpha | Vaak (30–79%) | In 1 aandoening |
| DPM3dolichyl-phosphate mannosyltransferase subunit 3, regulatory | Vaak (30–79%) | In 1 aandoening |
| EFEMP2EGF-like fibulin extracellular matrix protein 2 | Vaak (30–79%) | In 1 aandoening |
| ELNelastin | Vaak (30–79%) | In 1 aandoening |
| EPAS1endothelial PAS domain protein 1 | Vaak (30–79%) | In 1 aandoening |
| ERBB2erb-b2 receptor tyrosine kinase 2 | Vaak (30–79%) | In 1 aandoening |
| FBN1fibrillin 1 | Vaak (30–79%) | In 1 aandoening |
| FHfumarate hydratase | Vaak (30–79%) | In 1 aandoening |
| FOXE3forkhead box E3 | Vaak (30–79%) | In 1 aandoening |
| GATA4GATA binding protein 4 | Vaak (30–79%) | In 1 aandoening |
| GATA5GATA binding protein 5 | Vaak (30–79%) | In 1 aandoening |
| GATA6GATA binding protein 6 | Vaak (30–79%) | In 1 aandoening |
| GJA5gap junction protein alpha 5 | Vaak (30–79%) | In 1 aandoening |
| HBBhemoglobin subunit beta | Vaak (30–79%) | In 1 aandoening |
| HEY2hes related family bHLH transcription factor with YRPW motif 2 | Vaak (30–79%) | In 1 aandoening |
| HLA-Bmajor histocompatibility complex, class I, B | Vaak (30–79%) | In 1 aandoening |
Toon nog 103 genen
| Gen | Hoe vaak het voorkomt | Aandoeningen |
|---|---|---|
| HLA-DPA1major histocompatibility complex, class II, DP alpha 1 | Vaak (30–79%) | In 1 aandoening |
| HLA-DPB1major histocompatibility complex, class II, DP beta 1 | Vaak (30–79%) | In 1 aandoening |
| HLA-DQA1major histocompatibility complex, class II, DQ alpha 1 | Vaak (30–79%) | In 1 aandoening |
| HLA-DQB1major histocompatibility complex, class II, DQ beta 1 | Vaak (30–79%) | In 1 aandoening |
| HLA-DRB1major histocompatibility complex, class II, DR beta 1 | Vaak (30–79%) | In 3 aandoeningen |
| IL12Binterleukin 12B | Vaak (30–79%) | In 1 aandoening |
| KCNA5potassium voltage-gated channel subfamily A member 5 | Vaak (30–79%) | In 1 aandoening |
| KCNE1potassium voltage-gated channel subfamily E regulatory subunit 1 | Vaak (30–79%) | In 1 aandoening |
| KCNE2potassium voltage-gated channel subfamily E regulatory subunit 2 | Vaak (30–79%) | In 1 aandoening |
| KCNJ2potassium inwardly rectifying channel subfamily J member 2 | Vaak (30–79%) | In 1 aandoening |
| KCNJ3potassium inwardly rectifying channel subfamily J member 3 | Vaak (30–79%) | In 1 aandoening |
| KCNJ5potassium inwardly rectifying channel subfamily J member 5 | Vaak (30–79%) | In 1 aandoening |
| KCNQ1potassium voltage-gated channel subfamily Q member 1 | Vaak (30–79%) | In 1 aandoening |
| KIF1Bkinesin family member 1B | Vaak (30–79%) | In 1 aandoening |
| LAMP2lysosome associated membrane protein 2 | Vaak (30–79%) | In 1 aandoening |
| LOXlysyl oxidase | Vaak (30–79%) | In 1 aandoening |
| MAT2Amethionine adenosyltransferase 2A | Vaak (30–79%) | In 1 aandoening |
| MAXMYC associated transcriptional regulator X | Vaak (30–79%) | In 1 aandoening |
| MDH2malate dehydrogenase 2 | Vaak (30–79%) | In 1 aandoening |
| MEFVMEFV innate immunity regulator, pyrin | Vaak (30–79%) | In 3 aandoeningen |
| MFAP5microfibril associated protein 5 | Vaak (30–79%) | In 1 aandoening |
| MLXMAX dimerization protein MLX | Vaak (30–79%) | In 1 aandoening |
| MYH11myosin heavy chain 11 | Vaak (30–79%) | In 2 aandoeningen |
| MYH7myosin heavy chain 7 | Vaak (30–79%) | In 1 aandoening |
| MYL4myosin light chain 4 | Vaak (30–79%) | In 1 aandoening |
| MYLKmyosin light chain kinase | Vaak (30–79%) | In 1 aandoening |
| NF1neurofibromin 1 | Vaak (30–79%) | In 1 aandoening |
| NKX2-5NK2 homeobox 5 | Vaak (30–79%) | In 1 aandoening |
| NKX2-6NK2 homeobox 6 | Vaak (30–79%) | In 1 aandoening |
| NOS1nitric oxide synthase 1 | Vaak (30–79%) | In 1 aandoening |
| NPPAnatriuretic peptide A | Vaak (30–79%) | In 1 aandoening |
| NUP155nucleoporin 155 | Vaak (30–79%) | In 1 aandoening |
| PIGAphosphatidylinositol glycan anchor biosynthesis class A | Vaak (30–79%) | In 1 aandoening |
| PITX2paired like homeodomain 2 | Vaak (30–79%) | In 1 aandoening |
| PPOXprotoporphyrinogen oxidase | Vaak (30–79%) | In 1 aandoening |
| PRKG1protein kinase cGMP-dependent 1 | Vaak (30–79%) | In 1 aandoening |
| PRTN3proteinase 3 | Vaak (30–79%) | In 1 aandoening |
| PTPN22protein tyrosine phosphatase non-receptor type 22 | Vaak (30–79%) | In 1 aandoening |
| RETret proto-oncogene | Vaak (30–79%) | In 3 aandoeningen |
| RNF6ring finger protein 6 | Vaak (30–79%) | In 1 aandoening |
| SCN1Bsodium voltage-gated channel beta subunit 1 | Vaak (30–79%) | In 1 aandoening |
| SCN2Bsodium voltage-gated channel beta subunit 2 | Vaak (30–79%) | In 1 aandoening |
| SCN3Bsodium voltage-gated channel beta subunit 3 | Vaak (30–79%) | In 1 aandoening |
| SCN4Asodium voltage-gated channel alpha subunit 4 | Vaak (30–79%) | In 3 aandoeningen |
| SCN4Bsodium voltage-gated channel beta subunit 4 | Vaak (30–79%) | In 1 aandoening |
| SCN5Asodium voltage-gated channel alpha subunit 5 | Vaak (30–79%) | In 1 aandoening |
| SCNN1Asodium channel epithelial 1 subunit alpha | Vaak (30–79%) | In 1 aandoening |
| SCNN1Bsodium channel epithelial 1 subunit beta | Vaak (30–79%) | In 1 aandoening |
| SCNN1Gsodium channel epithelial 1 subunit gamma | Vaak (30–79%) | In 1 aandoening |
| SDHAsuccinate dehydrogenase complex flavoprotein subunit A | Vaak (30–79%) | In 1 aandoening |
| SDHAF2succinate dehydrogenase complex assembly factor 2 | Vaak (30–79%) | In 1 aandoening |
| SDHBsuccinate dehydrogenase complex iron sulfur subunit B | Vaak (30–79%) | In 2 aandoeningen |
| SDHCsuccinate dehydrogenase complex subunit C | Vaak (30–79%) | In 1 aandoening |
| SDHDsuccinate dehydrogenase complex subunit D | Vaak (30–79%) | In 2 aandoeningen |
| SLC25A11solute carrier family 25 member 11 | Vaak (30–79%) | In 1 aandoening |
| SLC34A2solute carrier family 34 member 2 | Vaak (30–79%) | In 1 aandoening |
| SMAD2SMAD family member 2 | Vaak (30–79%) | In 1 aandoening |
| SMAD3SMAD family member 3 | Vaak (30–79%) | In 1 aandoening |
| SMAD4SMAD family member 4 | Vaak (30–79%) | In 1 aandoening |
| TGFB2transforming growth factor beta 2 | Vaak (30–79%) | In 1 aandoening |
| TGFB3transforming growth factor beta 3 | Vaak (30–79%) | In 1 aandoening |
| TGFBR1transforming growth factor beta receptor 1 | Vaak (30–79%) | In 1 aandoening |
| TGFBR2transforming growth factor beta receptor 2 | Vaak (30–79%) | In 2 aandoeningen |
| THPOthrombopoietin | Vaak (30–79%) | In 1 aandoening |
| THSD4thrombospondin type 1 domain containing 4 | Vaak (30–79%) | In 1 aandoening |
| TMEM127transmembrane protein 127 | Vaak (30–79%) | In 1 aandoening |
| TTNtitin | Vaak (30–79%) | In 1 aandoening |
| VHLvon Hippel-Lindau tumor suppressor | Vaak (30–79%) | In 2 aandoeningen |
| WWOXWW domain containing oxidoreductase | Vaak (30–79%) | In 1 aandoening |
| ACTC1actin alpha cardiac muscle 1 | Soms (5–29%) | In 1 aandoening |
| ADAMTS19ADAM metallopeptidase with thrombospondin type 1 motif 19 | Soms (5–29%) | In 1 aandoening |
| APCAPC regulator of Wnt signaling pathway | Soms (5–29%) | In 1 aandoening |
| CAV3caveolin 3 | Soms (5–29%) | In 1 aandoening |
| CD4CD4 molecule | Soms (5–29%) | In 1 aandoening |
| CTNNB1catenin beta 1 | Soms (5–29%) | In 1 aandoening |
| DBHdopamine beta-hydroxylase | Soms (5–29%) | In 1 aandoening |
| DSG2desmoglein 2 | Soms (5–29%) | In 1 aandoening |
| GNASGNAS complex locus | Soms (5–29%) | In 3 aandoeningen |
| IRF4interferon regulatory factor 4 | Soms (5–29%) | In 1 aandoening |
| MT-TKmitochondrially encoded tRNA-Lys (AAA/G) | Soms (5–29%) | In 1 aandoening |
| MYL2myosin light chain 2 | Soms (5–29%) | In 1 aandoening |
| NDC1NDC1 transmembrane nucleoporin | Soms (5–29%) | In 1 aandoening |
| NOD2nucleotide binding oligomerization domain containing 2 | Soms (5–29%) | In 1 aandoening |
| PRKAG2protein kinase AMP-activated non-catalytic subunit gamma 2 | Soms (5–29%) | In 1 aandoening |
| PRKAR1Aprotein kinase cAMP-dependent type I regulatory subunit alpha | Soms (5–29%) | In 1 aandoening |
| RASA1RAS p21 protein activator 1 | Soms (5–29%) | In 1 aandoening |
| STAT3signal transducer and activator of transcription 3 | Soms (5–29%) | In 1 aandoening |
| STX16syntaxin 16 | Soms (5–29%) | In 1 aandoening |
| TNFRSF1ATNF receptor superfamily member 1A | Soms (5–29%) | In 1 aandoening |
| WASWASP actin nucleation promoting factor | Soms (5–29%) | In 1 aandoening |
| EXT1exostosin glycosyltransferase 1 | Zelden (1–4%) | In 1 aandoening |
| EXT2exostosin glycosyltransferase 2 | Zelden (1–4%) | In 1 aandoening |
| IRAK1interleukin 1 receptor associated kinase 1 | Zelden (1–4%) | In 1 aandoening |
| SAT1spermidine/spermine N1-acetyltransferase 1 | Zelden (1–4%) | In 1 aandoening |
| SPP1secreted phosphoprotein 1 | Zelden (1–4%) | In 1 aandoening |
| STAT4signal transducer and activator of transcription 4 | Zelden (1–4%) | In 1 aandoening |
| ENGendoglin | Niet vastgelegd | In 1 aandoening |
| MEF2Amyocyte enhancer factor 2A | Niet vastgelegd | In 1 aandoening |
| MYBPC3myosin binding protein C3 | Niet vastgelegd | In 1 aandoening |
| PLNphospholamban | Niet vastgelegd | In 1 aandoening |
| PPA2inorganic pyrophosphatase 2 | Niet vastgelegd | In 1 aandoening |
| TMEM43transmembrane protein 43 | Niet vastgelegd | In 1 aandoening |
| TNNC1troponin C1, slow skeletal and cardiac type | Niet vastgelegd | In 1 aandoening |
Hoe vaak dit voorkomt bij mensen met een van de aandoeningen van het gen, de hoogste frequentie binnen die aandoeningen, zoals de Human Phenotype Ontology dit vastlegt. Deze pagina's beschrijven kenmerken en het onderzoek erachter; het zijn geen diagnose, en over symptomen kunt u het best een arts of genetisch adviseur raadplegen.
Smallere kenmerken
Bredere kenmerken
Waar dit vandaan komt
- De Human Phenotype Ontology, release 2026-09-01: het kenmerk, de namen, de definitie en de genen die ermee verbonden zijn. Meer informatie vindt u op hpo.jax.org.
- Gegevensrelease 2026.10.16-c6eea6bf.
Voor wie we er zijnOnze wetenschapProductenResultaten
InloggenVraagAan de slagvanaf $ 449
Eén test. Een leven lang antwoorden.
Vanaf $ 449Gratis verzending · Resultaten binnen 6–8 weken